Hong Kong Aerospace & Defense Stock News

In January 2026, ANTA Sports Products reported that in 2025 its core ANTA brand delivered low single-digit retail sales growth, FILA achieved mid single-digit growth, and its other brands posted very large full-year gains compared with 2024. The company’s mixed fourth-quarter performance, ANTA brand sales slipping slightly while other brands grew strongly, highlights an ongoing shift in the balance of its multi-brand portfolio. Next, we’ll assess how this contrast between softer ANTA-branded...

On January 14, 2026, WuXi XDC Cayman Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference and issued unaudited guidance pointing to strong year‑on‑year increases in 2025 revenue, gross profit and net profit versus 2024. The company highlighted that gross profit is expected to grow faster than revenue, underlining improved margins and tighter cost control despite currency and interest rate headwinds. Next, we will examine how this anticipated margin expansion and profit growth...

China Shenhua Energy (SEHK:1088) is back in focus after releasing December and full year 2025 operating and sales figures, showing mixed trends across coal production, power generation, and its coal chemical products. See our latest analysis for China Shenhua Energy. The latest operating update comes after a solid run in the shares, with a 5.40% 1 month share price return and a 49.25% 1 year total shareholder return. This suggests momentum has been building as investors reassess China Shenhua...

Event driven view on Xtep International Holdings Xtep International Holdings (SEHK:1368) has kicked off its 2026 Southeast Asia push with new experience focused running hubs in Jakarta and Kuala Lumpur, putting more attention on how this expansion fits into the current share performance. See our latest analysis for Xtep International Holdings. The new Jakarta and Kuala Lumpur hubs arrive at a time when Xtep International Holdings’ share price is HK$5.23, with a 1 day share price return of...

Dekon Food and Agriculture Group recently announced that independent non-executive director Mr. Fung Che Wai, Anthony, has tendered his resignation, with veteran accountant Mr. Chan Yuk Tong nominated to succeed him as independent non-executive director, audit committee chairman and remuneration committee member after shareholder approval. Alongside this board transition, the company issued earnings guidance indicating that 2025 profit before biological assets fair value adjustments is...

In the past quarter, Genscript Biotech’s associate Legend Biotech reported approximately US$555 million in net trade sales of its multiple myeloma cell therapy CARVYKTI® for Q4 2025, while also highlighting the usual development, regulatory, and competitive risks facing such products. This sales performance underlines how CARVYKTI® has become an important proof point for Genscript’s broader biotech platform and positioning in advanced therapies. We’ll examine how CARVYKTI®’s commercial...

Hong Kong Exchanges and Clearing (SEHK:388) is expanding the Stock Connect program to include 98 new onshore ETFs for offshore investors. This is described as the largest expansion of eligible northbound products since Stock Connect was launched. The change broadens the range of Mainland China ETFs that can be accessed via Hong Kong. Hong Kong Exchanges and Clearing, which operates the stock and derivatives markets in Hong Kong, sits at the center of capital flows between Mainland China and...

361 Degrees International reported that fourth-quarter 2025 retail sales for its core and kids brands grew about 10% year-on-year, while e-commerce posted high double-digit growth, alongside ongoing expansion of premium stores and new product launches across running, basketball, outdoor, and kids segments. A distinctive angle is the company’s simultaneous push into global branding, becoming a certified supplier for major international sports events, while opening its first overseas Super...

Why Air China’s latest operating update matters for shareholders Air China (SEHK:753) just released detailed operating statistics for December 2025 and the full year, including passenger volumes, cargo tonnes and load factors. This gives investors fresh visibility into how its network is being utilized. See our latest analysis for Air China. Investors appear to be reacting to the detailed December and full year operating release. Air China’s recent 90 day share price return of 21.43% and 1...

In January 2026, Q Technology (Group) announced unaudited 2025 earnings guidance indicating consolidated profit is expected to be very large versus the approximately RMB 279,068,000 reported for 2024, supported by stronger demand for mid-to-high-end camera and fingerprint modules, better product mix, and operational upgrades. The guidance also reflects a growing contribution from non-handset camera modules in intelligent driving and IoT, alongside one-off gains from disposing part of its...

Event driven shift and why it matters for investors GoFintech Quantum Innovation (SEHK:290) has postponed its shareholder circular for a large artwork acquisition, with the document now expected by 20 February 2026. This extends the timetable for investor approval of this diversification move. See our latest analysis for GoFintech Quantum Innovation. The postponed circular comes after a very strong recent run in the shares, with a 30 day share price return of 16.41%, a 90 day return of...

Johnson Electric Holdings has scheduled its third-quarter 2026 earnings call for January 22, 2026, a key forum for updating investors on recent operating and financial developments. This upcoming call is drawing attention because management’s discussion of business conditions and outlook can significantly refresh how investors view the company’s fundamentals. With recent trading reflecting anticipation around the third-quarter earnings call, we’ll examine how this upcoming disclosure could...

Tencent Holdings (SEHK:700) has been drawing attention after recent share price moves, with the stock showing mixed returns over the past week, month and past 3 months. This has prompted investors to reassess its current valuation. See our latest analysis for Tencent Holdings. At around HK$597.5, Tencent’s recent share price softness, including a 7 day share price return of 3.94% decline and a 90 day share price return of 6.27% decline, contrasts with its 1 year total shareholder return of...

BYD has shipped over 5,800 electric and hybrid vehicles to Argentina under newly relaxed trade rules. The shipment is enabled by tariff free quotas for electric vehicles introduced by the Milei administration. This move expands BYD's presence in Latin America and adds pressure on Western and Japanese competitors. For investors tracking BYD (SEHK:1211), this Argentina move comes with the stock trading at HK$99.05 and a 3 year return of 35.4%. Over 1 year, the shares are up 8.6%, with a 5.7%...

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...

Why Akeso is on investors’ radars today Akeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day return of 7.6% decline from its last close of HK$114. Investors are weighing these short term moves against its longer term record and the company’s current fundamentals. See our latest analysis for Akeso. While the recent 1 day and 7 day share price returns are both in decline, Akeso’s 1 year total...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Abbisko Cayman (SEHK:2256) is back in focus after the U.S. FDA formally accepted the New Drug Application for pimicotinib, its oral CSF-1R inhibitor for tenosynovial giant cell tumor, following positive Phase III MANEUVER trial results. See our latest analysis for Abbisko Cayman. Investors appear to be weighing the FDA’s NDA acceptance against earlier gains, with a 1-month share price return of 7.85% and year to date share price return of 9.68%, while the 1-year total shareholder return is...

Xiaomi recently introduced a 7-year low-interest financing plan for its electric vehicles to lower monthly payments and improve affordability for first-time buyers, while CEO Lei Jun highlighted the importance of transparent marketing to build consumer trust. This move not only broadens access to Xiaomi’s EVs but also puts the spotlight on how financing design and credit risk management could influence the profitability of its auto ambitions. We will now examine how Xiaomi’s push into...

Ubtech Robotics (SEHK:9880) is back in focus after securing an Airbus order for its Walker S2 humanoid robots, following last year’s Texas Instruments deal and reporting over CN¥1.4b in humanoid robot orders for 2025. See our latest analysis for Ubtech Robotics. The Airbus order and pending acquisition circular come after a strong run in the stock, with a 30 day share price return of 27.19% and a 1 year total shareholder return of about 2.4x. This suggests momentum has picked up recently...

As global markets navigate a mixed landscape, with small-cap and value stocks gaining traction, investors are increasingly looking toward under-the-radar opportunities in Asia. Penny stocks, though often considered a relic of past trading days, still hold potential for significant growth when backed by strong financials. In this article, we explore three Asian penny stocks that stand out for their balance sheet strength and potential to uncover hidden value in today's market.

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Sunny Optical Technology (Group) (SEHK:2382) has launched a share repurchase program authorized to buy back up to 10% of its issued share capital, with the stated objective of supporting net asset value and earnings per share. See our latest analysis for Sunny Optical Technology (Group). The buyback announcement comes after a mixed stretch for investors, with the share price at HK$63.95 following a 2.16% 1 day share price return but a 18.59% 90 day share price decline and a 69.25% 5 year...

Earlier this month, Hansoh Pharmaceutical Group announced that China’s National Medical Products Administration approved an additional indication for its innovative lung cancer drug Ameile, allowing its use with pemetrexed and platinum-based chemotherapy as a first-line treatment for certain adult EGFR-mutated NSCLC patients, marking the drug’s fifth approved indication. This latest approval meaningfully broadens Ameile’s clinical footprint in lung cancer, underscoring Hansoh’s focus on...